Filana Therapeutics (MEX:FLNA) PS Ratio: (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:FLNA Filana Therapeutics Inc MEX:FLNA
34 GF Score
Price MXN23.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Filana Therapeutics's share price is MXN23.00. Filana Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0.00. Hence, Filana Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Filana Therapeutics's PS Ratio or its related term are showing as below:

MEX:FLNA's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.695
* Ranked among companies with meaningful PS Ratio only.

Filana Therapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was MXN0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0.00.

During the past 13 years, Filana Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 132.20% per year. The lowest was -43.70% per year. And the median was -23.15% per year.

Back to Basics: PS Ratio


Filana Therapeutics  (MEX:FLNA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Filana Therapeutics PS Ratio Related Terms


Filana Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics PS Ratio Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:FLNA vs BOLD, INKT, XLO: PS Ratio Comparison

For the Biotechnology subindustry, Filana Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Filana Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's PS Ratio falls into.


MEX:FLNA
34GF Score
Filana Therapeutics Inc MEX:FLNA
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Filana Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=23.00/0
=

Filana Therapeutics's Share Price of today is MXN23.00.
Filana Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
34GF Score

Get the complete analysis for MEX:FLNA

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN23.00
Price